Brief: Ocumension Therapeutics Says Ot-1001 (Zerviate) Included In Priority Review Of PRC's Nmpa
26/04/2023 11:14
April 26 (Reuters) - Ocumension Therapeutics 1477.HK :
* OT-1001 (ZERVIATE) INCLUDED IN PRIORITY REVIEW AND
APPROVAL
PROCESS OF NMPA OF PRC
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application